Previous 10 | Next 10 |
Summary Tyvaso is being explored by United Therapeutics Corporation in the TETON program (two phase 3 studies) which will determine if label expansion for idiopathic pulmonary fibrosis can be achieved. Tyvaso in an ad-hoc analysis in the short 16-week INCREASE study was shown to i...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology ( ESC ) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Soci...
Toast ( NYSE: TOST ) jumped in Friday's midday trading, boosted by quarterly results that exceeded analysts' projections. Liquidia ( LQDA ) represented another intraday standout, surging on developments in a patent case. Elsewhere, new IPO Forza X1 ( FRZA ) more than dou...
Liquidia Corp. ( NASDAQ: LQDA ) rose 8.6% after a judge issued an order suggesting that 793 patent should be considered invalid. The judge indicated that the Liquidia ( LQDA ) filed a notice with PTAB that invalidated all claims of the 793 patent. Recall LQDA ...
In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disea...
United Therapeutics Corporation (UTHR) Q2 2022 Results Conference Call August 3, 2022 09:00 AM ET Company Participants Dewey Steadman - Head, IR Dr. Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Dr. Leigh Peterson - SVP, Product Deve...
United Therapeutics press release ( NASDAQ: UTHR ): Q2 GAAP EPS of $2.41 misses by $1.55 . Revenue of $466.9M (+4.6% Y/Y) beats by $5.84M . “The recent approval and launch of Tyvaso DPI, coupled with the Medicare coverage decision for Tyvaso in PH-ILD, w...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarte...
United Therapeutics ( NASDAQ: UTHR ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $4.54 (+11.0% Y/Y) and the consensus Revenue Estimate is $461.06M (+3.3% Y/Y). Over the last 2 years, UTHR ha...
Shares of MannKind Corporation (NASDAQ: MNKD) , a biotech company that specializes in finding therapies for endocrine and orphan lung diseases, rose 10.4% on Monday. The stock closed at $3.45 on Friday and opened at that price on Monday. A little after 11 a.m., the stock reached its...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...